Phase II study of alisertib, a selective Aurora A kinase inhibitor, in relapsed and refractory aggressive B- and T-cell non-Hodgkin lymphomas (Q33410380)
Jump to navigation
Jump to search
scientific article
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | Phase II study of alisertib, a selective Aurora A kinase inhibitor, in relapsed and refractory aggressive B- and T-cell non-Hodgkin lymphomas |
scientific article |
Statements
1 reference
Phase II study of alisertib, a selective Aurora A kinase inhibitor, in relapsed and refractory aggressive B- and T-cell non-Hodgkin lymphomas (English)
1 reference
Izidore Lossos
1 reference
Jonathan W Friedberg
1 reference
Daruka Mahadevan
1 reference
Erin Cebula
1 reference
Daniel Persky
1 reference
Amit B Agarwal
1 reference
Jungah Jung
1 reference
Richard Burack
1 reference
Xiaofei Zhou
1 reference
E Jane Leonard
1 reference
Howard Fingert
1 reference
Hadi Danaee
1 reference
Steven H Bernstein
1 reference
16 September 2013
1 reference
1 reference
1 reference
1 reference
1 reference
Identifiers
1 reference